Critical care medicine
-
Critical care medicine · Jan 1996
Factors affecting the performance of the models in the Mortality Probability Model II system and strategies of customization: a simulation study.
To examine the impact of hospital mortality and intensive care unit (ICU) size on the performance of the Mortality Probability Model II system for use in quality assessment, and to examine the ability of model customization to produce accurate estimates of hospital mortality to characterize patients by severity of illness for clinical trials. ⋯ Mortality Probability Model II models can be used to assess quality of care in ICUs, but the size of the sample should be considered when assessing calibration and discrimination.
-
To develop a method based on admission day data for predicting patient outcome status as independently functional, compromised functional, or dead. ⋯ Prediction of three outcome states using physiologic status, baseline functional level, and broad-based diagnostic groupings at admission is feasible and may improve the relevance of quality of care assessment.
-
Critical care medicine · Jan 1996
Single breath CO2 analysis: description and validation of a method.
To evaluate the performance of a newly developed single breath CO2 analysis station in measuring the airway deadspace in a lung model (study 1), and then to quantify the bias and precision of the physiologic deadspace measurement in a surfactant-depleted animal model (study 2). ⋯ Our initial experience with the single breath CO2 analysis station indicates that this device can reliably provide on-line evaluation of the single-breath CO2 waveform. In particular, estimation of the airway and physiologic deadspace under a variety of testing conditions was consistently within 5% of actual values. We feel that with further application and refinement of the technique, single breath CO2 analysis may provide a noninvasive, on-line monitor of changes in pulmonary blood flow.
-
Critical care medicine · Jan 1996
Randomized Controlled Trial Multicenter Study Clinical TrialLiposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial.
To evaluate the safety and efficacy of liposomal prostaglandin E1 (TLC C-53) in the treatment of patients with the acute respiratory distress syndrome (ARDS). ⋯ In patients with ARDS, TLC C-53 was associated with improved oxygenation, increased lung compliance, and decreased ventilator dependency.